Spironolactone for heart failure with preserved ejection fraction

New England Journal of Medicine

Volumn 371, Issue 2, 2014, Pages 181-

  Morawietz, Henning ^a   Bornstein, Stefan R ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; SPIRONOLACTONE; MINERALOCORTICOID ANTAGONIST;

BLOOD LEVEL; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG RESPONSE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HUMAN; LETTER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; FEMALE; HEART FAILURE; MALE; NOTE;

FEMALE; HEART FAILURE; HUMANS; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; SPIRONOLACTONE;

EID: 84903898415     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1405715     Document Type: Letter

References (4)

1. McMurray JJV, O'Connor C. Lessons from the TOPCAT trial. N Engl J Med 2014;370:1453-4.
2. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17. (Pubitemid 29407370)
3. Krug AW, Kopprasch S, Ziegler CG, et al. Aldosterone rapidly induces leukocyte adhesion to endothelial cells: a new link between aldosterone and arteriosclerosis? Hypertension 2007;50(5):e156-e157. (Pubitemid 350287546)
4. Saha S, Schwarz PE, Bergmann S, Bornstein SR, Graessler J, Kopprasch S. Circulating very-low-density lipoprotein from subjects with impaired glucose tolerance accelerates adrenocortical cortisol and aldosterone synthesis. Horm Metab Res 2013;45:169-72.